Last updated on April 19, 2014 at 1:20 EDT

Pfizer’s (PFE) c.$12bn Zoetis, a Real Spinoff?

January 31, 2013

NEW YORK and LONDON, January 31, 2013 /PRNewswire/ –

“This is an IPO, not a Spinoff… Well not yet!” according to Ryan Mendy, COO of TSR
[http://www.spinoffreport.com/contact-us ], the UK based, leading global Spinoff and
special situations research firm.

http://photos.prnewswire.com/prnh/20130115/588743-b )

TSR’s specialist analyst team have been looking at Pfizer’s (PFE) various break-up
potentials closely since 2010. Zoetis (ZTS), PFE’s Animal Health business, is one of 120+
break-ups onTSR’s 2013 calendar,
[http://www.spinoffreport.com/research-services/us-spinoffs ] but they believe the best is
to come for investors.

“Zoetis is due to be priced today, valued at c.$12bn”, comments Mendy
[http://www.spinoffreport.com/contact-us ]. “Ourresearch
[http://www.spinoffreport.com/contact-us ] sees a better investment angle on PFE if you
want ZTS stock? Large investors are apparently oversubscribed to the IPO. There’s still
over two thirds [80%] of the company being held back by PFE management. Will they be
distributed tax-free? Much better returns are generated fromSpinoffs
[http://www.spinoffreport.com/research-services/us-spinoffs ] than IPOs”.

And the TSR team have a real edge, they returned +23% in FY2012 to funds using their
research and they have a market leading history of both advising and delivering
institutional clients solid benchmark outperforming returns from their fundamental
analysis, weekly idea generation and recommendations on what future Spinoffs
[http://www.spinoffreport.com/contact-us ] and Distressed Equity Situations
[http://www.distressedreport.com ] will perform best(?). You can click here to see TSR’s 5
year track record vs. major benchmarks.
[http://www.spinoffreport.com/research-model-portfolio ]

PFE, valued at $197bn, are merely selling (raising money) for 20% of ZTS and holding
back the rest to see how it performs, thus with no current tax-free distribution of the
other 80% of stock back to current PFE shareholders, this is a pure IPO, not a Spinoff
[http://www.spinoffreport.com/research-services/us-spinoffs ].

It appears Compuware (CPWR) [http://www.spinoffreport.com/contact-us ] is aiming to
carry out a similar process now, just like Sunoco (SUN)
[http://www.spinoffreport.com/contact-us ] did with its coke-making business SunCoke Energy
(SXC) [http://www.spinoffreport.com/contact-us ] and Dean Foods (DF)
[http://www.spinoffreport.com/contact-us ] is planning with its consumer segment, WhiteWave
(WWAV). [http://www.spinoffreport.com/contact-us ]

How to get more?

Click here to enquire [http://www.spinoffreport.com/contact-us ] regarding TSR’s
[http://www.spinoffreport.com/contact-us ] research of this and other Spinoff’s
[http://www.spinoffreport.com/research-services/european-report ] in the US, those in
Europe and all other international markets, as well as their upcoming deep value coverage

Investment sectors covered byThe Spinoff Report(R) [http://www.spinoffreport.com ]
&The Distressed Report(TM) [http://www.distressedreport.com ]:

Activism, Bankruptcy, Carve Outs, Deep Value, Catalysts, Demutualizations, Directors
Dealings, Distressed Securities, Liquidations, Merger Securities, Mergers & Acquisitions,
Post-Re-Orgs, Privatizations, Recapitalizations, Recovery Situations, Equity
Restructurings, Reverse Mergers, Reverse Morris Trusts, Rights Offerings, Special
Dividends, Spinoffs, Split-offs, Tender Offers and Turnarounds.

        Ryan Mendy, COO [http://www.spinoffreport.com/contact-us ]
        The Spinoff Report(R) (TSR)





SOURCE The Spinoff Report Ltd

Source: PR Newswire